Tags

Type your tag names separated by a space and hit enter

Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study.
J Endourol. 2005 Jan-Feb; 19(1):11-4.JE

Abstract

BACKGROUND AND PURPOSE

To assess in a prospective study whether shockwave therapy (SWT) is effective as a first-line treatment for Peyronie's disease.

PATIENTS AND METHODS

Forty patients with previously untreated Peyronie's disease underwent SWT with the Epos overhead-module device (Dornier). The pain severity (visual analog pain scale [VAS] 0-5), the degree of penile angulation after vasoactive drug injection, plaque size by ultrasound measurement, and erectile dysfunction (IIEF score) were assessed prior to and after treatment. Of the 40 patients, 7 underwent two sessions and the rest three sessions. The time interval between treatments was 2 weeks. At a power level of 2 to 5 (mean 4), a maximum of 3000 shockwaves per plaque per treatment were applied. The mean follow-up was 12 months.

RESULTS

All patients completed the protocol. The tolerance and safety were excellent. Of the 25 patients with pain on erection, 12 (48%) noticed relief after the first session, while 9 more were pain free at the end of the treatment (VAS reduction 2.8; P<0.0001, and 2; P<0.001, respectively). For 25 patients (62.5%), an improvement in penile angulation>20 degrees was observed, with a mean reduction of 35 degrees (range 20 degrees-60 degrees) (P<0.001). No significant change in plaque size was noted. Among 28 patients with erectile dysfunction, 18 (64.2%) had a marked increase in erection quality (IIEF score change: +4 for 10 patients, +6 for 4 patients, +8 for 2 patients, +9 for 2 patients).

CONCLUSION

Our results support SWT as an effective and safe first-line treatment for Peyronie's disease.

Authors+Show Affiliations

Skolarikos A
2nd Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. andskol@yahoo.com
Alargof E
No affiliation info available
Rigas A
No affiliation info available
Deliveliotis Ch
No affiliation info available
Konstantinidis E
No affiliation info available

MeSH

AdultAgedFollow-Up StudiesHumansLithotripsyMaleMiddle AgedPainPain MeasurementPenile ErectionPenile IndurationPilot ProjectsProspective StudiesTreatment OutcomeUltrasonography

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15735375

Citation

Skolarikos, A, et al. "Shockwave Therapy as First-line Treatment for Peyronie's Disease: a Prospective Study." Journal of Endourology, vol. 19, no. 1, 2005, pp. 11-4.
Skolarikos A, Alargof E, Rigas A, et al. Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. J Endourol. 2005;19(1):11-4.
Skolarikos, A., Alargof, E., Rigas, A., Deliveliotis, C. h., & Konstantinidis, E. (2005). Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. Journal of Endourology, 19(1), 11-4.
Skolarikos A, et al. Shockwave Therapy as First-line Treatment for Peyronie's Disease: a Prospective Study. J Endourol. 2005 Jan-Feb;19(1):11-4. PubMed PMID: 15735375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. AU - Skolarikos,A, AU - Alargof,E, AU - Rigas,A, AU - Deliveliotis,Ch, AU - Konstantinidis,E, PY - 2005/3/1/pubmed PY - 2005/6/10/medline PY - 2005/3/1/entrez SP - 11 EP - 4 JF - Journal of endourology JO - J Endourol VL - 19 IS - 1 N2 - BACKGROUND AND PURPOSE: To assess in a prospective study whether shockwave therapy (SWT) is effective as a first-line treatment for Peyronie's disease. PATIENTS AND METHODS: Forty patients with previously untreated Peyronie's disease underwent SWT with the Epos overhead-module device (Dornier). The pain severity (visual analog pain scale [VAS] 0-5), the degree of penile angulation after vasoactive drug injection, plaque size by ultrasound measurement, and erectile dysfunction (IIEF score) were assessed prior to and after treatment. Of the 40 patients, 7 underwent two sessions and the rest three sessions. The time interval between treatments was 2 weeks. At a power level of 2 to 5 (mean 4), a maximum of 3000 shockwaves per plaque per treatment were applied. The mean follow-up was 12 months. RESULTS: All patients completed the protocol. The tolerance and safety were excellent. Of the 25 patients with pain on erection, 12 (48%) noticed relief after the first session, while 9 more were pain free at the end of the treatment (VAS reduction 2.8; P<0.0001, and 2; P<0.001, respectively). For 25 patients (62.5%), an improvement in penile angulation>20 degrees was observed, with a mean reduction of 35 degrees (range 20 degrees-60 degrees) (P<0.001). No significant change in plaque size was noted. Among 28 patients with erectile dysfunction, 18 (64.2%) had a marked increase in erection quality (IIEF score change: +4 for 10 patients, +6 for 4 patients, +8 for 2 patients, +9 for 2 patients). CONCLUSION: Our results support SWT as an effective and safe first-line treatment for Peyronie's disease. SN - 0892-7790 UR - https://wwww.unboundmedicine.com/medline/citation/15735375/Shockwave_therapy_as_first_line_treatment_for_Peyronie's_disease:_a_prospective_study_ DB - PRIME DP - Unbound Medicine ER -